JP2015530359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530359A5 JP2015530359A5 JP2015521668A JP2015521668A JP2015530359A5 JP 2015530359 A5 JP2015530359 A5 JP 2015530359A5 JP 2015521668 A JP2015521668 A JP 2015521668A JP 2015521668 A JP2015521668 A JP 2015521668A JP 2015530359 A5 JP2015530359 A5 JP 2015530359A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- item
- tumors
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 8
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 7
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 7
- 230000005298 paramagnetic effect Effects 0.000 claims description 7
- 238000013319 spin trapping Methods 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 230000000139 costimulatory effect Effects 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 238000011319 anticancer therapy Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010029098 Neoplasm skin Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038111 Recurrent cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 208000025402 neoplasm of esophagus Diseases 0.000 claims description 2
- 208000025189 neoplasm of testis Diseases 0.000 claims description 2
- 230000003439 radiotherapeutic effect Effects 0.000 claims description 2
- 208000014680 small intestine neoplasm Diseases 0.000 claims description 2
- 208000021550 spleen neoplasm Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 208000025421 tumor of uterus Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000003054 hormonal effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 14
- 108020004705 Codon Proteins 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- 102000016799 Leukocyte elastase Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000000019 nipple aspirate fluid Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 208000013718 rectal benign neoplasm Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261669967P | 2012-07-10 | 2012-07-10 | |
| US61/669,967 | 2012-07-10 | ||
| US201261702916P | 2012-09-19 | 2012-09-19 | |
| US61/702,916 | 2012-09-19 | ||
| PCT/US2013/049368 WO2014011489A2 (en) | 2012-07-10 | 2013-07-03 | Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530359A JP2015530359A (ja) | 2015-10-15 |
| JP2015530359A5 true JP2015530359A5 (enExample) | 2016-08-25 |
| JP6336696B2 JP6336696B2 (ja) | 2018-06-06 |
Family
ID=49916655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521668A Active JP6336696B2 (ja) | 2012-07-10 | 2013-07-03 | がんおよび自己免疫疾患の診断および治療に使用するためのモノクローナル抗体 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9926380B2 (enExample) |
| EP (2) | EP2872174A2 (enExample) |
| JP (1) | JP6336696B2 (enExample) |
| KR (1) | KR102049222B1 (enExample) |
| CN (1) | CN104540522B (enExample) |
| AU (1) | AU2013288982B2 (enExample) |
| CA (1) | CA2883056C (enExample) |
| CY (1) | CY1121743T1 (enExample) |
| DK (1) | DK3088421T3 (enExample) |
| EA (1) | EA034033B1 (enExample) |
| ES (1) | ES2720291T3 (enExample) |
| HR (1) | HRP20190939T1 (enExample) |
| HU (1) | HUE043443T2 (enExample) |
| IL (1) | IL236664B (enExample) |
| IN (1) | IN2015DN00263A (enExample) |
| LT (1) | LT3088421T (enExample) |
| MX (1) | MX360984B (enExample) |
| PH (1) | PH12015500074B1 (enExample) |
| PL (1) | PL3088421T3 (enExample) |
| PT (1) | PT3088421T (enExample) |
| RS (1) | RS58755B1 (enExample) |
| SI (1) | SI3088421T1 (enExample) |
| UA (1) | UA114108C2 (enExample) |
| WO (1) | WO2014011489A2 (enExample) |
| ZA (1) | ZA201500247B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201404991YA (en) | 2012-02-23 | 2014-09-26 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| SG11201608557UA (en) * | 2014-04-16 | 2016-11-29 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| KR20180108567A (ko) | 2015-10-22 | 2018-10-04 | 주노 테라퓨틱스 게엠베하 | 형질도입을 위한 방법, 키트, 제제 및 장치 |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| IL263616B2 (en) | 2016-07-07 | 2025-01-01 | Univ Leland Stanford Junior | Antibody-adjuvant conjugates |
| IL270142B2 (en) | 2017-04-27 | 2025-05-01 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| US12290564B2 (en) | 2017-05-18 | 2025-05-06 | Renovorx, Inc. | Methods and apparatuses for treating tumors |
| MX2019015053A (es) | 2017-06-14 | 2020-02-13 | Adicet Bio Inc | Anticuerpos capaces de unirse a hla-a2/tyrd de forma restringida por hla y usos de estos. |
| CN108611322B (zh) * | 2018-05-09 | 2020-02-11 | 邹畅 | 乳腺癌循环肿瘤细胞系ctc-3、培养基及ctc-3的建立方法和应用 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| WO2021202798A1 (en) * | 2020-04-02 | 2021-10-07 | The United States Of America As Represented By The Secretary Of The Navy | Antigen binding proteins to class 5 etec adhesins |
| CA3227281A1 (en) * | 2021-07-26 | 2023-02-02 | Michael H. Cardone | Methods and compositions related to mcl-1 and bim heterodimer antibodies |
| WO2024102497A2 (en) * | 2022-11-11 | 2024-05-16 | Renovorx, Inc. | Methods and apparatuses for delivering an agent through the vasa vasorum |
| WO2025049921A1 (en) * | 2023-08-30 | 2025-03-06 | University Of Louisville Research Foundation, Inc. | Methods for single molecule resolution of near full-length immunoglobulin heavy and light chain repertoires |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4843092A (en) | 1986-04-25 | 1989-06-27 | Hitoshi Shichi | Immunosuppressive agent |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
| US5141648A (en) | 1987-12-02 | 1992-08-25 | Neorx Corporation | Methods for isolating compounds using cleavable linker bound matrices |
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| FR2658197B1 (fr) | 1990-02-14 | 1992-05-22 | Inst Nat Sante Rech Med | Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement. |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US7074904B2 (en) | 1994-07-29 | 2006-07-11 | Altor Bioscience Corporation | MHC complexes and uses thereof |
| US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US5846225A (en) | 1997-02-19 | 1998-12-08 | Cornell Research Foundation, Inc. | Gene transfer therapy delivery device and method |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6534633B1 (en) | 1998-10-21 | 2003-03-18 | Altor Bioscience Corporation | Polyspecific binding molecules and uses thereof |
| JP4447456B2 (ja) | 2001-06-05 | 2010-04-07 | アルトール バイオサイエンス コーポレーション | Ｐ５３結合ｔ細胞受容体分子とその使用 |
| US20100291102A1 (en) | 2001-07-02 | 2010-11-18 | Ice Biologics Limited | Therapeutic Agent |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| JPWO2004033499A1 (ja) | 2002-10-11 | 2006-02-09 | 中外製薬株式会社 | 細胞死誘導剤 |
| US20060167230A1 (en) | 2003-01-20 | 2006-07-27 | Takaki Koga | Anti-pci neutralizing antibody |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| WO2005056603A1 (ja) | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | 細胞死誘導剤 |
| US20090233318A1 (en) | 2004-12-28 | 2009-09-17 | Weidanz Jon A | Methods of assaying vaccine potency |
| US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090042285A1 (en) | 2004-05-27 | 2009-02-12 | Weidanz Jon A | Antibodies at T cell receptor mimics, methods of production and uses thereof |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20060045881A1 (en) | 2004-08-26 | 2006-03-02 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| US20060045884A1 (en) | 2004-08-26 | 2006-03-02 | Board Of Regents | Vaccines for autoimmune and infectious disease |
| EP1876236B9 (en) | 2005-04-08 | 2015-02-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| JPWO2006123724A1 (ja) | 2005-05-18 | 2008-12-25 | 国立大学法人徳島大学 | 抗ｈｌａ抗体を利用した新規医薬品 |
| CA2662798A1 (en) | 2005-09-07 | 2007-03-15 | Receptor Logic, Ltd. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| TW200808351A (en) | 2006-07-13 | 2008-02-16 | Chugai Pharmaceutical Co Ltd | Cell death-inducing agents |
| CL2008000719A1 (es) | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| WO2009073163A1 (en) | 2007-12-03 | 2009-06-11 | American Type Culture Collection (Atcc) | Avian influenza antibodies, compositions, and methods thereof |
| WO2010065962A2 (en) | 2008-12-05 | 2010-06-10 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease |
| TW201118166A (en) | 2009-09-24 | 2011-06-01 | Chugai Pharmaceutical Co Ltd | HLA class I-recognizing antibodies |
-
2013
- 2013-03-07 UA UAA201501025A patent/UA114108C2/uk unknown
- 2013-07-03 EA EA201590187A patent/EA034033B1/ru not_active IP Right Cessation
- 2013-07-03 US US14/413,833 patent/US9926380B2/en active Active
- 2013-07-03 WO PCT/US2013/049368 patent/WO2014011489A2/en not_active Ceased
- 2013-07-03 ES ES16152641T patent/ES2720291T3/es active Active
- 2013-07-03 PT PT16152641T patent/PT3088421T/pt unknown
- 2013-07-03 CN CN201380042522.1A patent/CN104540522B/zh active Active
- 2013-07-03 LT LTEP16152641.3T patent/LT3088421T/lt unknown
- 2013-07-03 CA CA2883056A patent/CA2883056C/en active Active
- 2013-07-03 PL PL16152641T patent/PL3088421T3/pl unknown
- 2013-07-03 RS RS20190609A patent/RS58755B1/sr unknown
- 2013-07-03 JP JP2015521668A patent/JP6336696B2/ja active Active
- 2013-07-03 AU AU2013288982A patent/AU2013288982B2/en active Active
- 2013-07-03 EP EP13816335.7A patent/EP2872174A2/en not_active Withdrawn
- 2013-07-03 HU HUE16152641A patent/HUE043443T2/hu unknown
- 2013-07-03 SI SI201331371T patent/SI3088421T1/sl unknown
- 2013-07-03 IN IN263DEN2015 patent/IN2015DN00263A/en unknown
- 2013-07-03 KR KR1020157003610A patent/KR102049222B1/ko active Active
- 2013-07-03 EP EP16152641.3A patent/EP3088421B1/en active Active
- 2013-07-03 MX MX2015000450A patent/MX360984B/es active IP Right Grant
- 2013-07-03 DK DK16152641.3T patent/DK3088421T3/da active
-
2015
- 2015-01-11 IL IL236664A patent/IL236664B/en active IP Right Grant
- 2015-01-12 PH PH12015500074A patent/PH12015500074B1/en unknown
- 2015-01-14 ZA ZA2015/00247A patent/ZA201500247B/en unknown
-
2018
- 2018-02-13 US US15/895,782 patent/US11192958B2/en active Active
-
2019
- 2019-05-07 CY CY20191100490T patent/CY1121743T1/el unknown
- 2019-05-21 HR HRP20190939TT patent/HRP20190939T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015530359A5 (enExample) | ||
| ES2968880T3 (es) | Receptor de antígeno quimérico (CAR) que se une a BCMA, y usos del mismo | |
| CN113286879B (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| ES2778651T3 (es) | Receptores de antígeno quimérico y métodos de uso | |
| AU2014225788B2 (en) | Engager cells for immunotherapy | |
| US20210252056A1 (en) | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective immunotherapy | |
| JP2022501043A (ja) | 抗ｃｄ１２３免疫療法によりがんを処置するための組成物および方法 | |
| JP2024178177A (ja) | 抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法 | |
| JP7035170B2 (ja) | 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法 | |
| JP2020533958A (ja) | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 | |
| CN106632660A (zh) | 识别ny‑eso‑1抗原短肽的tcr | |
| US20220168344A1 (en) | Compositions and methods for treating cancer with self-driving chimeric antigen receptors | |
| JP2024054286A (ja) | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 | |
| JP2022513682A (ja) | 抗ｃｄ３８免疫療法によりがんを処置するための組成物および方法 | |
| JP2025131569A (ja) | 抗ｂｃｍａ免疫療法によりがんを処置するための組成物および方法 | |
| AU2013271428A1 (en) | Human bispecific EGFRvIII antibody engaging molecules | |
| US20220242960A1 (en) | Ghr-106 chimeric antigen receptor construct and methods of making and using same | |
| US9611321B2 (en) | Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies | |
| EP4200322A1 (en) | Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation | |
| CN114195894A (zh) | 一种靶向4-1bb的抗体及其应用 | |
| CN106478808A (zh) | 识别ny-eso-1抗原短肽的t细胞受体 | |
| CN106632658B (zh) | 识别ny-eso-1抗原短肽的tcr | |
| JP2022514815A (ja) | ＣＤＲ１領域に突然変異したヒト化ＣＤ１９ ｓｃＦｖを有するＣＡＲ－Ｔ細胞 | |
| CN106188274A (zh) | 识别rhamm抗原短肽的t细胞受体 | |
| CN113423822A (zh) | Psca car-t细胞 |